how to wean off compounded semaglutide Stop Safely: Weaning Guide Stopping GLP-1s Safely: What to

Ridker PM, MacFadyen JG, Everett BM et al (2018) Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

it is generally understood to act centrally rather than primarily at the site of inflammation

Any new or worsening symptoms while on therapy, including severe abdominal pain, persistent nausea or vomiting, or signs of gallbladder disease, require prompt medical evaluation

This is speculative, but it represents a more logical use case than running both compounds simultaneously at full dose

Li W, Yu S-W, Kong A-NT